Phoenix Biotech Acquisition Corp. Class A (PBAX) has released an update.
CERo is in the running to receive a grant worth $4-6 million from the Cancer Focus Fund at MD Anderson for a clinical trial of its leading drug candidate, CER-1236, aimed at treating acute myeloid leukemia. This funding opportunity, however, comes with no guarantees as it hinges on meeting specific conditions and approvals, with uncertainties still in the mix.
For further insights into PBAX stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
